Bayer stock trades at EUR 49.37 after a plus 0.65 percent move versus EUR 49.05

Published on 09/30/2026 at 11:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On September 30, 2026, Bayer stock stood at EUR 49.37, plus 0.65 percent versus EUR 49.05. Deutsche Bank kept its Buy rating and EUR 60.00 target after first-half sales reached EUR 24.3 billion.

Forscherin im weißen Kittel pipettiert an einem beleuchteten Laborarbeitsplatz vor einem Bildschirm mit 3D-Molekülstruktur — Pharmazeutisches Forschungslabor – Wissenschaftlerin mit Pipette, Molekülstruktur-Monitor, blaue LED-Beleuchtung, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) was trading at EUR 49.37 at Lang & Schwarz on September 30, 2026 at 10:53 a.m. CEST, plus 0.65 percent versus the prior close of EUR 49.05. Deutsche Bank Research kept its Buy rating and EUR 60.00 price target on September 29, 2026, according to finanzen.ch. The target stands 21.53 percent above the Lang & Schwarz price, giving the analyst call a clear valuation reference.

Deutsche Bank keeps EUR 60 target

The September 29 assessment leaves the Buy recommendation and EUR 60.00 target unchanged. The cited outlook expects Bayer's third-quarter operating sales to grow 1.30 percent year over year, with the company scheduled to report its third-quarter figures on November 3, 2026, according to finanzen.ch.

That estimate sits against a mixed operating picture. Bayer's first-half sales increased 3 percent to EUR 24.3 billion, while core earnings per share reached EUR 3.66, according to the Q2 2026 earnings call published by Yahoo Finance. The figures give investors a quantified benchmark for the 2026 outlook rather than relying only on the price target.

First-half EBITDA rises 7 percent

EBITDA before special items rose 7 percent to EUR 6.6 billion in the first six months of 2026. Second-quarter sales increased 2 percent to EUR 10.9 billion, while second-quarter EBITDA before special items rose 2 percent to EUR 2.1 billion, according to Yahoo Finance.

The balance sheet remains central to the investment case. Bayer reported net financial debt of EUR 33.6 billion at the end of the second quarter, while litigation-related payouts reached EUR 2.5 billion in the first half, according to the same Q2 2026 call. Management reiterated its full-year 2026 outlook and projected net financial debt of EUR 29.0 billion to EUR 30.0 billion.

Hybrid bonds add EUR 2 billion

Bayer placed EUR 2 billion of hybrid bonds on September 23, 2026, lifting outstanding hybrid bonds to EUR 6.55 billion. The two 30-year tranches carry coupons of 5.75 percent and 6.25 percent, and Bayer said the instruments receive 50 percent equity recognition from rating agencies in its release.

The financing improves flexibility but also highlights why debt reduction remains a key stock issue. The combination of first-half sales growth, higher EBITDA and the lower debt target gives the current Bayer discussion two competing reference points: operating execution and financial leverage.

Bayer stock trades near EUR 50

Bayer stock was trading at EUR 49.37 at Lang & Schwarz on September 30, 2026 at 10:53 a.m. CEST, plus 0.65 percent versus the prior close of EUR 49.05. The market capitalization was EUR 48.5 billion on September 30, 2026, and the 52-week range was EUR 25.78 to EUR 53.92.